[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP3749751A4 - Compositions and methods for the induction of cd8+ t-cells - Google Patents

Compositions and methods for the induction of cd8+ t-cells Download PDF

Info

Publication number
EP3749751A4
EP3749751A4 EP19750643.9A EP19750643A EP3749751A4 EP 3749751 A4 EP3749751 A4 EP 3749751A4 EP 19750643 A EP19750643 A EP 19750643A EP 3749751 A4 EP3749751 A4 EP 3749751A4
Authority
EP
European Patent Office
Prior art keywords
induction
compositions
cells
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19750643.9A
Other languages
German (de)
French (fr)
Other versions
EP3749751A1 (en
Inventor
Kenya Honda
Takeshi Tanoue
Yutaka Kawakami
Koji Atarashi
Satoru Morita
Ashwin Nicholas SKELLY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keio University
Original Assignee
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University filed Critical Keio University
Publication of EP3749751A1 publication Critical patent/EP3749751A1/en
Publication of EP3749751A4 publication Critical patent/EP3749751A4/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • A61K2035/115Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • A61K2039/55594Adjuvants of undefined constitution from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP19750643.9A 2018-02-09 2019-02-08 Compositions and methods for the induction of cd8+ t-cells Pending EP3749751A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862628501P 2018-02-09 2018-02-09
US201862673436P 2018-05-18 2018-05-18
US201862737318P 2018-09-27 2018-09-27
US201862756029P 2018-11-05 2018-11-05
US201962795506P 2019-01-22 2019-01-22
PCT/JP2019/004703 WO2019156234A1 (en) 2018-02-09 2019-02-08 Compositions and methods for the induction of cd8+ t-cells

Publications (2)

Publication Number Publication Date
EP3749751A1 EP3749751A1 (en) 2020-12-16
EP3749751A4 true EP3749751A4 (en) 2022-02-23

Family

ID=67549651

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19750643.9A Pending EP3749751A4 (en) 2018-02-09 2019-02-08 Compositions and methods for the induction of cd8+ t-cells

Country Status (8)

Country Link
US (1) US11723934B2 (en)
EP (1) EP3749751A4 (en)
JP (2) JP2021512638A (en)
CN (1) CN111886333A (en)
AU (1) AU2019217041B2 (en)
CA (1) CA3088505A1 (en)
TW (1) TWI844525B (en)
WO (1) WO2019156234A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018117263A1 (en) 2016-12-23 2018-06-28 Keio University Compositions and methods for the induction of cd8+ t-cells
MX2022005157A (en) * 2019-11-01 2022-08-31 Uti Lp Harnessing the power of microbiota and metabolites for the treatment of cancer.
EP4362961A1 (en) * 2021-06-28 2024-05-08 Vedanta Biosciences, Inc. Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease
CN115806893B (en) * 2021-09-13 2023-10-20 中国科学技术大学 Application of bacteroides vulgaris and composition thereof in assisting cancer immunotherapy
CN118742322A (en) * 2021-12-15 2024-10-01 得克萨斯州大学系统董事会 Methods and compositions for altering tumor microbiome
CN115094035B (en) * 2022-05-26 2024-08-02 中山大学 Method for in-vitro expansion induction of T cells into tissue colonisation memory T cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121298A2 (en) * 2013-02-04 2014-08-07 Seres Health, Inc. Methods of populating a gastrointestinal tract
WO2015077794A1 (en) * 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2016196605A1 (en) * 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3249504A (en) * 1962-03-13 1966-05-03 Becton Dickinson Co Multiple unit tissue culture preparation and method of preparing same
BRPI0311909A8 (en) * 2002-06-19 2018-02-06 Nutricia Nv METHODS FOR MANUFACTURING A COMPOSITION, AND FOR INCREASE THE METHYLATION CAPACITY OF A SUBJECT, AND, PHARMACEUTICAL OR NUTRITIONAL COMPOSITION
US20050106194A1 (en) * 2003-11-18 2005-05-19 Mary Kay Inc. Compositions for achieving benefits in skin using key cellular metabolic intermediates
CA3151350A1 (en) 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
KR101829201B1 (en) * 2009-05-11 2018-02-19 베르그 엘엘씨 Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2779418C (en) 2009-11-11 2018-03-20 Alimentary Health Limited Probiotic bifidobacterium strain
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc Simultaneous inhibition of pd-l1/pd-l2
CN116942833A (en) 2011-12-01 2023-10-27 国立大学法人 东京大学 Human bacteria inducing proliferation or accumulation of regulatory T cells
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP4461372A2 (en) 2013-11-05 2024-11-13 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
EP2876167A1 (en) * 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
MX2016013247A (en) * 2014-04-10 2017-05-03 Riken Compositions and methods for induction of th17 cells.
CA2966132A1 (en) 2014-10-23 2016-04-28 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
EP3012270A1 (en) 2014-10-23 2016-04-27 Institut Gustave Roussy Products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
CN107636146A (en) * 2015-03-02 2018-01-26 同生公司 It is engineered to treat the bacterium of the disease for the gastrointestinal mucosal barrier benefited from the alimentary canal inflammation of reduction and/or tightened up
WO2018117263A1 (en) 2016-12-23 2018-06-28 Keio University Compositions and methods for the induction of cd8+ t-cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121298A2 (en) * 2013-02-04 2014-08-07 Seres Health, Inc. Methods of populating a gastrointestinal tract
WO2015077794A1 (en) * 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2016196605A1 (en) * 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM MINCHEOL ET AL: "Towards a taxonomic coherence between average nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of prokaryotes", INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, vol. 64, no. Pt_2, February 2014 (2014-02-01), GB, pages 346 - 351, XP055877627, ISSN: 1466-5026, DOI: 10.1099/ijs.0.059774-0 *
See also references of WO2019156234A1 *

Also Published As

Publication number Publication date
JP2021512638A (en) 2021-05-20
JP7503335B2 (en) 2024-06-20
US20220133813A1 (en) 2022-05-05
CN111886333A (en) 2020-11-03
EP3749751A1 (en) 2020-12-16
US11723934B2 (en) 2023-08-15
AU2019217041B2 (en) 2022-09-15
CA3088505A1 (en) 2019-08-15
TW202003834A (en) 2020-01-16
TWI844525B (en) 2024-06-11
JP2022130413A (en) 2022-09-06
WO2019156234A1 (en) 2019-08-15
AU2019217041A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
EP3559209A4 (en) Compositions and methods for the induction of cd8+ t-cells
EP3765608A4 (en) Gene-regulating compositions and methods for improved immunotherapy
EP3765094A4 (en) Gene-regulating compositions and methods for improved immunotherapy
IL288754A (en) Compositions and methods for cancer immunotherapy
IL282225A (en) Compositions and methods for immunotherapy
EP3589373A4 (en) Compositions and methods for immunotherapy
EP3589646A4 (en) Cd19 compositions and methods for immunotherapy
EP3823673A4 (en) Anti-cd112r compositions and methods
EP3638289A4 (en) Pde5 compositions and methods for immunotherapy
EP3749751A4 (en) Compositions and methods for the induction of cd8+ t-cells
EP3765092A4 (en) Gene-regulating compositions and methods for improved immunotherapy
EP3493827A4 (en) Compositions and methods for immunotherapy
EP3773718A4 (en) Compositions and methods comprising anti-nrp2 antibodies
EP3500262A4 (en) Compositions and methods for cancer immunotherapy
EP3891272A4 (en) Compositions and methods for immunotherapy
EP3752194A4 (en) Compositions and methods for tumor immunotherapy
EP3829307A4 (en) Bismuth-thiol compositions and methods of use
EP3807319A4 (en) Compositions and methods for inducing phagocytosis
EP3790577A4 (en) Compositions and methods concerning immune tolerance
EP3844500A4 (en) Rp182 compositions and methods
EP3630846A4 (en) Compositions and methods of cellular immunotherapy
EP3917546A4 (en) Gene-regulating compositions and methods for improved immunotherapy
EP3843729A4 (en) Novel compositions and methods
EP3897615A4 (en) Cannabis compositions and methods
IL283076A (en) Methods and compositions for cancer immunotherapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200804

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220126

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 1/20 20060101ALI20220120BHEP

Ipc: C07K 16/28 20060101ALI20220120BHEP

Ipc: A61K 45/06 20060101ALI20220120BHEP

Ipc: A61K 39/395 20060101ALI20220120BHEP

Ipc: A23L 33/135 20160101ALI20220120BHEP

Ipc: C12N 15/09 20060101ALI20220120BHEP

Ipc: A61P 35/00 20060101ALI20220120BHEP

Ipc: A61P 31/00 20060101ALI20220120BHEP

Ipc: A61K 35/74 20150101ALI20220120BHEP

Ipc: A61K 31/198 20060101ALI20220120BHEP

Ipc: A61K 31/19 20060101ALI20220120BHEP

Ipc: C12N 1/00 20060101ALI20220120BHEP

Ipc: A61K 39/00 20060101ALI20220120BHEP

Ipc: A61K 39/39 20060101AFI20220120BHEP